Teva’s Partner Antares Swallowed Up By Halozyme In $960m Deal
Teva/Antares Alliance Offers Gx EpiPen; US Forteo Rival Under Development
For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.
